Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis
Gerben A. Koning(Università Cattolica del Sacro Cuore), Gert Storm(Yong In University), Grietje Molema(University Medical Center Groningen), Robbert J. Kok(Utrecht University), Enrico Mastrobattista(Utrecht University), Timo L.M. ten Hagen(Erasmus MC), Marca H. M. Wauben(University of Applied Sciences Utrecht), Raymond M. Schiffelers(University Medical Center Utrecht)
Cited by 182
Related Papers
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
|Frontiers in Pharmacology|2018|937
TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility
|The Oncologist|2006|711
Sheddable Coatings for Long-Circulating Nanoparticles
|Pharmaceutical Research|2007|549
MIFlowCyt‐EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments
|Journal of Extracellular Vesicles|2020|514
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461